Genetic Signatures (ASX:GSS) has unveiled an organisational overhaul aimed at sharpening its commercial focus while significantly reducing costs, marking a pivotal moment in the company’s next phase of growth.
The restructuring follows an internal operations review and is designed to better align resources with strategic priorities. The plan focuses on revenue, customer engagement, and expanding the diagnostic product portfolio, while reducing internal structures that no longer support the company's direction.
As part of the changes, the company is consulting with employees about consolidating functions, which is expected to result in up to 30 redundancies. While the human impact is acknowledged, leadership has framed the move as necessary to create a leaner, more sustainable operating base.
The company estimates that, combined with broader efficiency measures, the restructure will deliver approximately $5 million in annual cost savings from the 2027 financial year. One-off redundancy costs are expected to reach around $800,000.
A feature of the transformation is the transition of certain product development activities to external contract research organisations. By outsourcing these components while retaining core intellectual property and technical expertise internally, Genetic Signatures aims to gain flexibility, access specialised capabilities, and accelerate time-to-market. This model is also intended to reduce fixed costs and allow greater investment in customer-facing operations and sales growth.
Alongside operational changes, the company is doubling down on expanding its product offering. Efforts will include advancing new diagnostic initiatives and strengthening the clinical evidence supporting its existing products. The broader goal is to address a wider range of clinical needs and penetrate new market segments across global healthcare systems.
Chief Executive Officer Maria Halasz described the restructure as the first step in a broader effort to reinforce operational discipline while positioning the business for long-term success. She emphasised the importance of balancing cost control with continued innovation and effective commercialisation of the company’s diagnostic technologies.
Chair Caroline Waldron acknowledged the challenges posed by the changes, particularly for employees affected by the transition, while underscoring the importance of the move in positioning the company for sustainable growth. She confirmed that impacted staff would receive full entitlements in line with company policy and legal requirements.